Back

GenePHIT phase 2 study design: a double blind, placebo-controlled trial to assess efficacy, safety, and tolerability of AB-1002 gene therapy in adults with heart failure

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiovascular risk and interventions: comparisons, disparities, and clinical trials Trial Design ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Luke Roberts

Reading (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Education level and the incidence of heart failure, acute myocardial infarction, and stroke in patients with atrial fibrillation
Doctor A. Sztaniszlav (Orebro, SE)
Abstract Slides Video
Presentation thumbnail
Association of ticagrelor vs clopidogrel with net adverse clinical events in NSTEMI patients with mild thrombocytopenia
Professor K. Chen (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Factors associated with major adverse cardiovascular events among Arabs and Jews in Israel: a population-based cohort study
Associate Professor O. Kalter-Leibovici (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Assessing aortic morphology post aortic valve replacement using unsupervised hierarchical clustering and statistical shape modelling
Mr Y. Aljassam (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
Sub-Saharan Africa's contribution to clinical trials in international acute coronary syndromes and heart failure guidelines
Doctor J. Hudson (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular risk and interventions: comparisons, disparities, and clinical trials

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure
thumbnail
Congress Presentation
Safety and efficacy of a phase 1 clinical gene therapy trial in patients with advanced heart failure using a rationally designed cardiotropic AAV vector targeting protein phosphatase inhibitor-1
thumbnail
Congress Presentation
PKP2 gene therapy reduces ventricular arrhythmias, reverses ventricular remodeling, improves heart function, and reduces mortality in a mouse model of arrhythmogenic right ventricular cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources